SCN2A-related disorders

What SCN2A-related disorders are

SCN2A provides the instructions for NaV1.2, a sodium channel that helps nerve cells fire, especially early in development. Changes in this single gene can cause a strikingly broad range of conditions: a severe developmental and epileptic encephalopathy beginning in the first weeks or months of life, milder self-limiting infant epilepsies, later-onset epilepsies, and autism spectrum disorder or intellectual disability with few or no seizures.

The crucial gain- versus loss-of-function distinction

Unlike many genes, SCN2A variants split into two opposite groups, and the difference is central to treatment.

• Gain-of-function (overactive channel) — typically causes seizures very early, usually before 3 months of age. Importantly, these seizures often respond well to sodium-channel-blocking medicines (such as phenytoin, carbamazepine, oxcarbazepine or lacosamide).
• Loss-of-function (underactive channel) — typically causes later-onset seizures (after about 3 months) and/or autism and intellectual disability, sometimes with no early seizures at all. Here, sodium-channel-blocking medicines can make seizures worse and are generally avoided.
• Because of this, the age at which seizures begin (before or after roughly 3 months) is a practical clue to which mechanism — and therefore which treatment — is likely to apply.

How it presents and how it is diagnosed

Depending on the variant, children may present with neonatal or early-infantile seizures, later-onset epilepsy, developmental delay or intellectual disability, autism, or movement difficulties. Diagnosis is made by genetic testing — usually an epilepsy gene panel or exome sequencing — supported by EEG and MRI. Increasingly, laboratories and specialists also try to classify whether a variant is gain- or loss-of-function, because this guides treatment.

Current management

Antiseizure medicines are chosen according to the mechanism: sodium-channel blockers for early-onset, gain-of-function seizures, and broad-spectrum medicines (avoiding sodium-channel blockers) for loss-of-function presentations. The ketogenic diet may be considered in resistant cases. For children with autism or intellectual disability, multidisciplinary developmental support — speech and language therapy, occupational therapy and educational support — is central, whether or not seizures are present.

The genetic pipeline: precision therapy

Because SCN2A disorders are caused by a single gene, they are a leading target for precision therapy — and the right approach depends entirely on the mechanism.

• Gain-of-function — elsunersen (PRAX-222, Praxis Precision Medicines) is an antisense oligonucleotide, given into the spinal fluid, that selectively reduces SCN2A expression to counter the overactive channel. In April 2026 the EMBRAVE Part A trial reported positive results, with about a 77% reduction in seizures in children with early-seizure-onset SCN2A developmental and epileptic encephalopathy; the FDA has aligned on an accelerated registrational pathway and the EMA has granted PRIME designation. An individually designed antisense oligonucleotide has also been used in a preterm infant, with around a 60% reduction in seizures.
• Loss-of-function — here the opposite is needed: to increase NaV1.2 rather than reduce it. Expression-boosting antisense and gene-therapy approaches are being developed but remain at an earlier, mostly preclinical stage.

How an educational review can help

SCN2A is unusually dependent on the precise variant and its functional effect, which can make the genetics confusing and the treatment choices counter-intuitive. An educational review can explain the genetic report and the gain- versus loss-of-function distinction in plain language, clarify why a particular medicine was chosen or deliberately avoided, and put the emerging antisense therapy in honest context.

It is an educational second opinion — not a diagnosis, treatment or prescription — and it does not replace the care of your child's own clinicians.